HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines

International Journal of Molecular Sciences

Volumn 14, Issue 3, 2013, Pages 6026-6043

  Li, Jinping ^a,b,c   Chen, Haibin ^d   Mariani, Andrea ^b   Chen, Dong ^b   Klatt, Edward ^a   Podratz, Karl ^b   Drapkin, Ronny ^e   Broaddus, Russell ^f   Dowdy, Sean ^b   Jiang, Shi Wen ^a,b,c  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^d SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colony formation; Endometrial cancer; HE4 variant; Human epididymis protein 4 (HE4); Invasion; Proliferation; Tumorigenesis

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; EXPRESSION VECTOR; GLYCOSYLATION; MOUSE; NONHUMAN; PROTEIN CONFORMATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TUMOR GROWTH; WESTERN BLOTTING;

EUKARYOTA;

EID: 84875542690     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14036026     Document Type: Article

References (43)

1. National Cancer Institute. SEER Stat Fact Sheets: Corpus and Uterus, NOS. Available online: http://seer.cancer.gov/statfacts/html/corp.html (accessed on 12 March 2013).
2. Bingle, L.; Singleton, V.; Bingle, C.D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002, 21, 2768-2773.
3. Hellstrom, I.; Raycraft, J.; Hayden-Ledbetter, M.; Ledbetter, J.A.; Schummer, M.; McIntosh, M.; Drescher, C.; Urban, N.; Hellstrom, K.E. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63, 3695-3700.
4. Drapkin, R.; von Horsten, H.H.; Lin, Y.; Mok, S.C.; Crum, C.P.; Welch, W.R.; Hecht, J.L. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65, 2162-2169.
5. Jiang, S.-W.; Dowdy, S.C.; Fu, A.; Attewell, J.R.; Kalogera, E.; Drapkin, R.; Podratz, K.C.; Broaddus, R.; Li, J. HE4 Transcription-and splice variants-specific expression in 8 endometrial cancer and correlation with patient survival. Int. J. Mol. Sci. 2013, submitted for publication.
6. Galgano, M.T.; Hampton, G.M.; Frierson, H.F., Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod. Pathol. 2006, 19, 847-853.
7. DeSouza, L.V.; Grigull, J.; Ghanny, S.; Dube, V.; Romaschin, A.D.; Colgan, T.J.; Siu, K.W. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol. Cell Proteomics 2007, 6, 1170-1182.
8. Li, H.; DeSouza, L.V.; Ghanny, S.; Li, W.; Romaschin, A.D.; Colgan, T.J.; Siu, K.W. Identification of candidate biomarker proteins released by human endometrial and cervical cancer cells using two-dimensional liquid chromatography/tandem mass spectrometry. J. Proteome Res. 2007, 6, 2615-2622.
9. Moore, R.G.; Brown, A.K.; Miller, M.C.; Badgwell, D.; Lu, Z.; Allard, W.J.; Granai, C.O.; Bast, R.C., Jr.; Lu, K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol. 2008, 110, 196-201.
10. Bignotti, E.; Ragnoli, M.; Zanotti, L.; Calza, S.; Falchetti, M.; Lonardi, S.; Bergamelli, S.; Bandiera, E.; Tassi, R.A.; Romani, C.; et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br. J. Cancer 2011, 104, 1418-1425.
11. Kamei, M.; Yamashita, S.; Tokuishi, K.; Hashioto, T.; Moroga, T.; Suehiro, S.; Ono, K.; Miyawaki, M.; Takeno, S.; Yamamoto, S.; Kawahara, K. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer Res. 2010, 30, 4779-4783.
12. Bouchard, D.; Morisset, D.; Bourbonnais, Y.; Tremblay, G.M. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol. 2006, 7, 167-174.
13. Micci, F.; Teixeira, M.R.; Haugom, L.; Kristensen, G.; Abeler, V.M.; Heim, S. Genomic aberrations in carcinomas of the uterine corpus. Genes Chromosomes Cancer 2004, 40, 229-246.
14. Scholler, N.; Crawford, M.; Sato, A.; Drescher, C.W.; O'Briant, K.C.; Kiviat, N.; Anderson, G.L.; Urban, N. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin. Cancer Res. 2006, 12, 2117-2124.
15. Scholler, N.; Lowe, K.A.; Bergan, L.A.; Kampani, A.V.; Ng, V.; Forrest, R.M.; Thorpe, J.D.; Gross, J.A.; Garvik, B.M.; Drapkin, R.; et al. Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin. Cancer Res. 2008, 14, 2647-2655.
16. Moore, R.G.; Brown, A.K.; Miller, M.C.; Skates, S.; Allard, W.J.; Verch, T.; Steinhoff, M.; Messerlian, G.; DiSilvestro, P.; Granai, C.O.; Bast, R.C., Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 2008. 108, 402-408.
17. Hellstrom, I.; Hellstrom, K.E. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv. Exp. Med. Biol. 2008, 622, 15-22.
18. Moore, R.G.; Jabre-Raughley, M.; Brown, A.K.; Robison, K.M.; Miller, M.C.; Allard, W.J.; Kurman, R.J.; Bast, R.C.; Skates, S.J. Comparison of a novel multiple marker assay vs the risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am. J. Obstet. Gynecol. 2010, 203, 228e1-6.
19. Havrilesky, L.J.; Whitehead, C.M.; Rubatt, J.M.; Cheek, R.L.; Groelke, J.; He, Q.; Malinowski, D.P.; Fischer, T.J.; Berchuck, A. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol. Oncol. 2008, 110, 374-382.
20. Yurkovetsky, Z.; Skates, S.; Lomakin, A.; Nolen, B.; Pulsipher, T.; Modugno, F.; Marks, J.; Godwin, A.; Gorelik, E.; Jacobs, I.; et al. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 2010, 28, 2159-2166.
21. Huhtinen, K.; Suvitie, P.; Hiissa, J.; Junnila, J.; Huvila, J.; Kujari, H.; Setala, M.; Harkki, P.; Jalkanen, J.; Fraser, J.; et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 2009, 100, 1315-1319.
22. Park, Y.; Kim, Y.; Lee, E.Y.; Lee, J.H.; Kim, H.S. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int. J. Cancer 2012, 130, 1136-1144.
23. Ruggeri, G.; Bandiera, E.; Zanotti, L.; Belloli, S.; Ravaggi, A.; Romani, C.; Bignotti, E.; Tassi, R.A.; Tognon, G.; Galli, C.; et al. HE4 and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin. Chim. Acta 2011, 412, 1447-1453.
24. Shah, C.A.; Lowe, K.A.; Paley, P.; Wallace, E.; Anderson, G.L.; McIntosh, M.W.; Andersen, M.R.; Scholler, N.; Bergan, L.A.; Thorpe, J.D.; et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol. Biomarkers Prev. 2009, 18, 1365-1372.
25. Anastasi, E.; Granato, T.; Marchei, G.G.; Viggiani, V.; Colaprisca, B.; Comploj, S.; Reale, M.G.; Frati, L.; Midulla, C. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol. 2010, 31, 411-415.
26. Anderson, G.L.; McIntosh, M.; Wu, L.; Barnett, M.; Goodman, G.; Thorpe, J.D.; Bergan, L.; Thornquist, M.D.; Scholler, N.; Kim, N.; et al. Assessing lead time of selected ovarian cancer biomarkers: A nested case-control study. J. Natl. Cancer Inst. 2010, 102, 26-38.
27. Granato, T.; Midulla, C.; Longo, F.; Colaprisca, B.; Frati, L.; Anastasi, E. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol. 2012, 33, 1335-1339.
28. Yoshida, N.; Egami, H.; Yamashita, J.; Takai, E.; Tamori, Y.; Fujino, N.; Kitaoka, M.; Schalkwijk, J.; Ogawa, M. Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of human lung. Oncol. Rep. 2002, 9, 495-501.
29. Westin, U.; Nystrom, M.; Ljungcrantz, I.; Eriksson, B.; Ohlsson, K. The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. Mediators Inflamm. 2002, 11, 7-12.
30. Clauss, A.; Ng, V.; Liu, J.; Piao, H.; Russo, M.; Vena, N.; Sheng, Q.; Hirsch, M.S.; Bonome, T.; Matulonis, U.; et al. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia 2010, 12, 161-172.
31. Kluger, H.M.; Chelouche Lev, D.; Kluger, Y.; McCarthy, M.M.; Kiriakova, G.; Camp, R.L.; Rimm, D.L.; Price, J.E. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res. 2005, 65, 5578-5587.
32. Devoogdt, N.; Hassanzadeh Ghassabeh, G.; Zhang, J.; Brys, L.; de Baetselier, P.; Revets, H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 5778-5782.
33. Idoji, Y.; Watanabe, Y.; Yamashita, A.; Yamanishi, K.; Nishiguchi, S.; Shimada, K.; Yasunaga, T.; Yamanishi, H. In silico study of whey-acidic-protein domain containing oral protease inhibitors. Int. J. Mol. Med. 2008, 21, 461-468.
34. Kalogera, E.; Scholler, N.; Powless, C.; Weaver, A.; Drapkin, R.; Li, J.; Jiang, S.W.; Podratz, K.; Urban, N.; Dowdy, S.C. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol. Oncol. 2012, 124, 270-275.
35. Lu, K.H.; Patterson, A.P.; Wang, L.; Marquez, R.T.; Atkinson, E.N.; Baggerly, K.A.; Ramoth, L.R.; Rosen, D.G.; Liu, J.; Hellstrom, I.; et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 2004, 10, 3291-3300.
36. Li, J.; Dowdy, S.; Tipton, T.; Podratz, K.; Lu, W.G.; Xie, X.; Jiang, S.W. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev. Mol. Diagn. 2009, 9, 555-566.
37. Scott, R.E.; Wille, J.J., Jr.; Wier, M.L. Mechanisms for the initiation and promotion of carcinogenesis: A review and a new concept. Mayo Clin. Proc. 1984, 59, 107-117.
38. Sanchez-Tillo, E.; Liu, Y.; de Barrios, O.; Siles, L.; Fanlo, L.; Cuatrecasas, M.; Darling, D.S.; Dean, D.C.; Castells, A.; Postigo, A. EMT-activating transcription factors in cancer: Beyond EMT and tumor invasiveness. Cell Mol. Life Sci. 2012, 69, 3429-3456.
39. Yang, J.; Zhu, J.; Sun, D.; Ding, A. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. Biochim. Biophys. Acta 2005, 1745, 310-317.
40. McNeely, T.B.; Shugars, D.C.; Rosendahl, M.; Tucker, C.; Eisenberg, S.P.; Wahl, S.M. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997, 90, 1141-1149.
41. Van Dekken, H.; Alers, J.C.; Riegman, P.H.; Rosenberg, C.; Tilanus, H.W.; Vissers, K. Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions. Am. J. Pathol. 2001, 158, 1961-1967.
42. Jin, F.; Dowdy, S.C.; Xiong, Y.; Eberhardt, N.L.; Podratz, K.C.; Jiang, S.W. Up-regulation of DNA methyltransferase 3B expression in endometrial cancers. Gynecol. Oncol. 2005, 96, 531-538.
43. Zeng, H.; Datta, K.; Neid, M.; Li, J.; Parangi, S.; Mukhopadhyay, D. Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem. Biophys. Res. Commun. 2003, 302, 46-55.